Elicio Therapeutics announces IDMC positive recommendation to continue Phase 2 pancreatic cancer trial to final analysis

Elicio Therapeutics, Inc.

IDMC recommended AMPLIFY-7P trial continue to final analysis without modifications based on pre-specified interim review of safety and efficacy.
Final disease-free survival analysis anticipated in Q4 2025; company remains blinded to trial outcomes.
Cash runway extends into Q1 2026, past the expected final DFS readout.
Elicio previously reached FDA alignment on key elements of planned pivotal Phase 3 study design.
ELI-002 7P is an off-the-shelf immunotherapy targeting seven KRAS mutations in pancreatic ductal adenocarcinoma.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.